Exelixis Inc. Stock

In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.

That's precisely what could happen

The healthcare sector underperformed broader equities in 2025, but that shouldn't deter investors. Many companies in the industry performed relatively well and appear to be solid buy-and-hold

Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to

Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is